Lumiracoxib
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Musculoskeletal Pain
Conditions
Musculoskeletal Pain
Trial Timeline
Nov 1, 2004 → —
NCT ID
NCT00170898About Lumiracoxib
Lumiracoxib is a approved stage product being developed by Novartis for Musculoskeletal Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT00170898. Target conditions include Musculoskeletal Pain.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00419796 | Approved | Completed |
| NCT00333567 | Approved | Completed |
| NCT00350155 | Approved | Completed |
| NCT00348491 | Approved | Completed |
| NCT00267176 | Approved | Completed |
| NCT00170781 | Approved | Completed |
| NCT00170898 | Approved | Completed |
| NCT00170872 | Phase 3 | Completed |
| NCT00145301 | Phase 3 | Completed |
| NCT00475800 | Phase 3 | Completed |
| NCT00476034 | Phase 3 | Completed |
| NCT00366938 | Phase 3 | Completed |
| NCT00367315 | Phase 3 | Completed |
| NCT00267215 | Phase 3 | Completed |
Competing Products
4 competing products in Musculoskeletal Pain
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Eperisone hydrochloride and Diclofenac sodium + Eperisone hydrochloride | Eisai | Phase 3 | 77 |
| No intervention | Johnson & Johnson | Pre-clinical | 23 |
| ACE-083 | Merck | Phase 1 | 33 |
| Nerve Growth Factor | Lundbeck | Pre-clinical | 20 |